<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190714044207N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-07-25</date_registration>
      <primary_sponsor>Zahedan University of Medical Sciences</primary_sponsor>
      <public_title>The sedation effect of midazolam-fentanyl and midazolam-propofol combination in patients with elective upper gastrointestinal endoscopy in Ali ebne Abitaleb Hospital, Zahedan, in 2018</public_title>
      <acronym>ZSGIE</acronym>
      <scientific_title>The sedation effect of midazolam-fentanyl and midazolam-propofol combination in patients with elective upper gastrointestinal endoscopy in Ali ebne Abitaleb Hospital, Zahedan, in 2018</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>140</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/40829</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Selection and assignment of samples to each treatment group is done by random blocking method. The number of cards in each block will be in the case and control groups, the arrangement of each card of the groups in the block, taking into account the random order with the examples of the permutations, will be arranged, Blinding description: Patients, Anesthetist, Gastroenterologist are unaware of the allocation of study groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: The sedative effect of the medication on endoscopic digestive system. Condition 2: The sedative effect of the medication on endoscopic digestive system.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: IV infusion of midazolam + fentanyl (F), midazolam, mcg / kg 15, fentanyl 0.15 mg / kg. Intervention 2: Intervention group:IV infusion of midazolam + propofol (P ) Midazolam 15mcg / kg and Propofol 1mg / kg.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Doctor Sakineh Sheikh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Salamat Blvd., Persian Gulf Highway, Zahedan</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9816743463</zip>
        <telephone>+98 54 3329 5715</telephone>
        <email>sakine.sheikh@gmail.com</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sakineh Sheikh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Third  Intersection, No. 12 Shahid Barfi street, Shahid Barfi Ave</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9816743463</zip>
        <telephone>+98 54 3343 4621</telephone>
        <email>mmahjoubifard@zaums.ac.ir</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patient candidated for upper GI endoscopy
20-70 years old
ASA class ≤3</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Heart disease AS، IHD ، HTN،(HF EF&lt;30%)
Liver disease (Child-Pugh classification C)
Renal disease  (GFR&lt;60%)
Lack of patient cooperation
Psychiatric Disease (Major Depression, Mania, Psychosis)
SBP&lt;90
Addiction
Emergent endoscopy
Allergy to egg and soybean</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R10</hc_code>
      <hc_code>R19</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Abdominal and pelvic pain</hc_keyword>
      <hc_keyword>Other symptoms and signs involving the digestive system and abdomen</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: IV infusion of midazolam + fentanyl (F), midazolam, mcg / kg 15, fentanyl 0.15 mg / kg</i_keyword>
      <i_keyword>Intervention group:IV infusion of midazolam + propofol (P ) Midazolam 15mcg / kg and Propofol 1mg / kg</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sedation of drugs in both groups before and after endoscopy. Timepoint: From the start of the drug (time 0) and every 5 minutes, it is recorded until the patient is transferred to the recovery room. Method of measurement: Ramsay sedation score (0-5).</prim_outcome>
      <prim_outcome>The number of respiration in both groups before and after endoscopy. Timepoint: From the start of the drug (time 0) and every 5 minutes, it is recorded until the patient is transferred to the recovery room. Method of measurement: Vital signs Monitor device.</prim_outcome>
      <prim_outcome>The number of heart rate in both groups before and after endoscopy. Timepoint: From the start of the drug (time 0) and every 5 minutes, it is recorded until the patient is transferred to the recovery room. Method of measurement: Vital signs Monitor device.</prim_outcome>
      <prim_outcome>Blood Pressure in both groups before and after endoscopy. Timepoint: From the start of the drug (time 0) and every 5 minutes, it is recorded until the patient is transferred to the recovery room. Method of measurement: Vital signs Monitor device.</prim_outcome>
      <prim_outcome>Arterial oxygen saturation in both groups before and after endoscopy. Timepoint: From the start of the drug (time 0) and every 5 minutes, it is recorded until the patient is transferred to the recovery room. Method of measurement: Vital signs Monitor device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Comparison of vital signs after endoscopy. Timepoint: When the patient is transferred to the recovery room. Method of measurement: Monitoring device of vital signs.</sec_outcome>
      <sec_outcome>The satisfaction of sefation of two drug regimens. Timepoint: After Endoscopy End. Method of measurement: Anesthesiology Resident Skill and Experience.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zahedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-01-26</approval_date>
        <contact_name>Ethics committee of Zahedan University of Medical Sciences</contact_name>
        <contact_address>ZAUMS Main campus, Zahedan, Sistan and Baluchestan, Iran Zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
